Testosterone Suppression in the Treatment of Recurrent or Metastatic Prostate Cancer – A Canadian Consensus Statement

Tom Pickles, MB, MD, MRCP, FRCPC
Professor, University of British Columbia
Department of Surgery
Division of Radiotherapy and Developmental Radiotherapeutics
Vancouver, BC

Objectives:

- Understand the potential benefit of a testosterone suppression to ≤0.7 nmol/L during ADT
- Learn practical steps to ensure timely, accurate and reliable assay of low testosterone levels in the context of ADT
  - Recommended testing frequency
  - Assay selection and implications for accurate measurement
  - Communication with clinical labs
- Interpret testosterone assay results relative to PSA levels and apply this to clinical management strategy

Hosted by: Radiation Oncology

THANK YOU TO OUR SPONSORS:

REFRESHMENTS WILL BE PROVIDED
Department of Oncology, Schulich School of Medicine & Dentistry
London Regional Cancer Program